See more : ispace, inc. (9348.T) Income Statement Analysis – Financial Results
Complete financial analysis of BriaCell Therapeutics Corp. (BCTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BriaCell Therapeutics Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Protean eGov Technologies Limi (PROTEAN.BO) Income Statement Analysis – Financial Results
- Xplus S.A. (XPL.WA) Income Statement Analysis – Financial Results
- Orora Limited (ORRYY) Income Statement Analysis – Financial Results
- Burnpur Cement Limited (BURNPUR.NS) Income Statement Analysis – Financial Results
- Brookfield Reinsurance Ltd. (BAMR) Income Statement Analysis – Financial Results
BriaCell Therapeutics Corp. (BCTX)
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 82.58K | 15.53K | 15.14K | 15.57K | 13.99K | 14.27K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -82.58K | -15.53K | -15.14K | -15.57K | -13.99K | -14.27K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 26.75M | 15.34M | 8.02M | 1.32M | 2.22M | 3.74M | 2.39M | 1.71M | 723.43K | 105.82K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.15M | 7.94M | 7.27M | -3.67M | -1.37M | -932.17K | -1.05M | 876.16K | 942.02K | 1.33M | 436.17K | 423.86K | 556.06K | 1.05M | 323.27K | 203.86K | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | -178.93K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.97M | 7.94M | 7.27M | -3.67M | -1.37M | -932.17K | -1.05M | 876.16K | 942.02K | 1.33M | 436.17K | 423.86K | 556.06K | 1.05M | 323.27K | 203.86K | 114.12K | 129.06K | 8.58K |
| Other Expenses | 0.00 | 0.00 | -15.29M | -1.33M | -2.24M | -3.75M | -312.92K | 290.00 | 1.79K | 565.00 | 1.21K | 404.00 | -4.23K | 2.40K | 1.33K | 2.33K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 32.73M | 23.27M | -3.39K | -3.69M | -1.38M | -946.42K | -1.07M | 2.58M | 1.67M | 1.44M | 437.27K | 424.26K | 551.84K | 1.05M | 324.57K | 233.87K | 114.12K | 129.06K | 8.58K |
| Cost & Expenses | 32.81M | 23.27M | -3.39K | -3.69M | -1.38M | -946.42K | -1.07M | 2.58M | 1.67M | 1.44M | 437.27K | 424.26K | 551.84K | 1.05M | 324.57K | 233.87K | 114.12K | 129.06K | 8.58K |
| Interest Income | 0.00 | 891.21K | 136.73K | 3.15K | 39.48 | 9.13K | 12.27K | 5.16K | 3.63K | 7.09K | 12.00K | 16.90K | 38.01K | 13.36K | 2.90K | 2.73K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 979.00 | 46.10K | 27.00K | 23.82K | 15.63K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 82.58K | 15.27K | 15.27K | 15.26K | 15.26K | 14.25K | 12.97K | 232.68 | 907.21 | 434.31 | 1.11K | 392.08 | 1.72K | 2.51K | 1.29K | 154.20 | 12.72K | 5.10K | -1.13K |
| EBITDA | -4.77M | -30.67M | -15.13M | -8.69M | -3.97M | -6.67M | -4.96M | -3.22M | -2.18M | -1.80M | -2.61K | -462.53K | -68.23K | -1.01M | 255.79K | -233.72K | -114.12K | -129.06K | -8.58K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -32.81M | -23.27M | -15.29M | 3.69M | 1.38M | 946.42K | -3.82M | -2.58M | -1.67M | -1.44M | -437.27K | -424.26K | -1.20M | -1.05M | -324.57K | -233.87K | -114.12K | -129.06K | -8.58K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 28.02M | 2.97M | 3.74M | -6.84M | -85.10K | 0.00 | -1.59M | 634.11K | 481.60K | -1.24M | -7.71M | 55.56K | 202.71K | -37.17K | -595.34K | 2.51K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -4.79M | -20.30M | -11.55M | 3.69M | 1.38M | 946.42K | 1.07M | -2.58M | -1.70M | -2.68M | -8.15M | -368.69K | -995.72K | -1.09M | -919.91K | -231.36K | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 62.85K | -152.62K | 30.73K | 6.58M | -72.25K | 343.74K | 1.59M | 638.59K | 547.97K | 2.05M | 8.45M | -44.35K | -200.92K | -24.03K | 601.48K | 12.46K | -12.72K | -5.10K | 1.13K |
| Net Income | -4.79M | -20.30M | -11.58M | -2.89M | 1.38M | 602.68K | 1.07M | -2.58M | -1.70M | -2.68M | -8.15M | -368.69K | -995.72K | -1.08M | -900.74K | -228.81K | -98.93K | -116.41K | -8.58K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.29 | -1.30 | -0.75 | -0.64 | 1.94 | 1.04 | 2.49 | -7.61 | -5.88 | -10.76 | -138.07 | -6.25 | -16.93 | -33.02 | -49.58 | -25.62 | -20.45 | -27.92 | -4.18 |
| EPS Diluted | -0.29 | -1.30 | -0.75 | -0.64 | 1.94 | 1.04 | 2.49 | -7.32 | -5.88 | -10.76 | -138.07 | -6.25 | -16.93 | -33.02 | -49.58 | -25.62 | -20.45 | -27.92 | -4.18 |
| Weighted Avg Shares Out | 16.45M | 15.62M | 15.49M | 4.52M | 713.89K | 579.66K | 427.81K | 339.71K | 288.44K | 249.18K | 59.00K | 59.00K | 58.83K | 32.67K | 18.17K | 8.93K | 4.84K | 4.17K | 2.05K |
| Weighted Avg Shares Out (Dil) | 16.45M | 15.62M | 15.49M | 4.52M | 713.89K | 579.66K | 427.82K | 352.98K | 288.44K | 249.18K | 59.00K | 59.00K | 58.83K | 32.67K | 18.17K | 8.93K | 4.84K | 4.17K | 2.05K |
Short Squeeze Stocks: PROG, SAVA and 3 Others Experts Think Are Ready to Pop
Fintel's list of short squeeze stocks to watch for this week is in. Here are the names that investors should be watching.
BriaCell's Survival Story Could Mean a Better Chance of Survival for Women Suffering from Breast Cancer
Photo by Artem Podrez from Pexels Too many companies and small businesses to count were buried under the avalanche of a global pandemic in the past 18 months. And as horrible as it was to lose your favorite restaurant or...
BriaCell, ImaginAb Join Forces To Assess Imaging Tech In Breast Cancer Trial
BriaCell Therapeutics Corp (NASDAQ: BCTX) has announced a multi-year, non-exclusive license agreement with ImaginAb Inc for developing next-generation immuno-oncology imaging agents and radiopharmaceutical therapies. Under the agreement terms, ImaginAb will supply clinical doses of its CD8 ImmunoPET technology (89Zr-Df-Crefmirlimab) to BriaCell for use in BriaCell's...
BriaCell Therapeutics Attacks Cancer with Novel Off-the-Shelf Immunotherapies
Photo by Chokniti Khongchum from Pexels In 2020, there were 2.3 million women globally diagnosed with breast cancer and 685,000 deaths, according to the World Health Organization. In the U.S., 12.9% of women born in the country today will develop...
BriaCell's Early-Stage Combination Study In Advanced Breast Cancer Starts Enrollment
BriaCell Therapeutics Corp (NASDAQ: BCTX) has opened recruitment and enrollment of their collaborative clinical study with Incyte Corporation (NASDAQ: INCY). The Phase 1/2a combination study will evaluate BriaCell's lead candidate, Bria-IMT, with Incyte's retifanlimab & epacadostat to treat advanced breast cancer.
BCTX Stock Price Increased 8.96%: Why It Happened
The stock price of BriaCell Therapeutics Corp. (Nasdaq: BCTX) increased by 8.96% yesterday. This is why it happened.
Why Shares Of BriaCell Therapeutics Surged Today
BriaCell Therapeutics Corp (NASDAQ: BCTX) shares are trading higher on Wednesday after the company announced it is expanding its breast cancer platform into prostate, melanoma and lung cancers. The expansion includes Bria-Pros for prostate cancer, Bria-Mel for melanoma and Bria-Lung for lung cancer and...
BriaCell Extends Personalized Breast Cancer Immunotherapy To Prostate & Lung Cancer And Melanoma
BriaCell Therapeutics Corp (NASDAQ: BCTX) has advanced its targeted oncology therapeutics into several novel immunotherapy cell lines, including - Bria-Pros for prostate cancer, Bria-Mel for melanoma, and Bria-Lung for lung cancer. The company anticipates commencing clinical trials for these novel therapies in 2022.
BriaCell Therapeutics Corp. Announces Closing of US$27.2 Million Private Placement
BERKELEY, Calif. and VANCOUVER, British Columbia, June 07, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW)(TSX-V:BCT) (the "Company" or “BriaCell”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announced that it has closed...
BriaCell Reports 12.0 Months Overall Survival Benefit in Advanced Breast Cancer; 100% Resolution of ‘Eye-Bulging' Tumor
BERKELEY, Calif. and VANCOUVER, British Columbia, June 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today provides an update on...
Source: https://incomestatements.info
Category: Stock Reports